Catalent Pharma invests $5m in drug development center of excellence to expand its hot melt extrusion capabilities for formulation and drug delivery method optimization.
Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
CTI expects to create up to 50 new jobs over the next several years in response to significant growth in the pharma and biotech industry, specifically in cell and gene therapies, says CEO.
Metrion Biosciences looks to partner and move its lead candidate into clinical trials later this year fueled by a funding round which will also see its drug discovery services expand throughout 2019.
Clinical trials often rely on outsourced testing which poses potential logistical and cost challenges, though researchers recently demonstrated the viability of bringing these tests in-house to speed turnaround time – and more quickly match patients to...
With 70% of its customers in North America and demand increasing, the UK-based CDMO Sterling Pharma Solutions has acquired CiVentiChem’s US facility in Cary, North Carolina.
The discussion surrounding clinical trial awareness has evolved “from mere conversations to action, creativity, and inclusivity from multiple stakeholders,” and will continue to evolve as we work together to create a paradigm shift in awareness, says...
Since finalizing its risk-based monitoring guidance in 2013, the FDA is providing additional information in a new Q&A that reinforces the importance of performing risk assessments for all studies.
TriNetX acquires Belgium-based Custodix NV to support industry partners looking to collaborate with non-US hospitals – becoming a “one-stop-shop” for clinical data, says SVP.
Horizon Discovery is working with St George’s University Hospital and EMQN to develop reference material for non-invasive prenatal testing, which is being increasingly adopted in the UK and abroad.
Sinclair Research and Turner Scientific sign an exclusive partnership through which the CROs will offer ototoxicity testing services – and improve regulatory guidance regarding the ears to protect patients, says company executive.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
